Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
Tuesday, 01 January 2019 23:06
Logo
Jan. 2, 2019 21:05 UTC

Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 4:30 p.m. Pacific time. The conference will be held at the Westin St. Francis Hotel in San Francisco.

A live webcast of the presentation and Q&A session can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco and Oakland, California and Cambridge, UK. Please visit clovisoncology.com for more information.

Contacts

Clovis Oncology
Anna Sussman
303.625.5022
[email protected]
or
Breanna Burkart
303.625.5023
[email protected]


Source: Clovis Oncology




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter